Market capitalization | $119.25m |
Enterprise Value | $75.48m |
P/E (TTM) P/E ratio | 195.89 |
EV/FCF (TTM) EV/FCF | 12.95 |
EV/Sales (TTM) EV/Sales | 2.07 |
P/S ratio (TTM) P/S ratio | 3.27 |
P/B ratio (TTM) P/B ratio | 2.77 |
Revenue growth (TTM) Revenue growth | 42.00% |
Revenue (TTM) Revenue | $36.43m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
4 Analysts have issued a Brainsway Ltd Sponsored ADR forecast:
4 Analysts have issued a Brainsway Ltd Sponsored ADR forecast:
Jun '24 |
+/-
%
|
||
Revenue | 36 36 |
42%
42%
|
|
Gross Profit | 27 27 |
46%
46%
|
|
EBITDA | 2.02 2.02 |
116%
116%
|
EBIT (Operating Income) EBIT | 0.73 0.73 |
105%
105%
|
Net Profit | 0.61 0.61 |
105%
105%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Brainsway Ltd. is a commercial stage medical device company, which focuses on the development and sale of non-invasive neuromodulation products using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.
Head office | Israel |
CEO | Hadar Levy |
Employees | 106 |
Founded | 2006 |
Website | www.brainsway.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.